Delving into the Latest Updates on Allogeneic dental pulp mesenchymal stem cell therapy (Beijing SH Bio-Tech Corporation/Utooth Biological Technology) with Synapse

The primary objective:To evaluate the efficacy of different administration protocols of human dental pulp mesenchymal stem cells for the treatment of chronic periodontitis patients.
The secondary objective:To evaluate the safety of different administration protocols of human dental pulp mesenchymal stem cells for the treatment of chronic periodontitis patients.
The exploratory objective:To investigate the effects of human dental pulp mesenchymal stem cells on biomarkers in gingival crevicular fluid in chronic periodontitis patients.

Start Date27 Nov 2023

Sponsor / Collaborator

Peking University Third Hospital

[+1]

JPRN-UMIN000050735

/ CompletedNot ApplicableIIT

Wrinkle-improving effect of an all-in-one gel containing "Immortalized Human Tooth Pulp Stem Cell Conditioned Media" and "Human Cord Blood Stem Cell Conditioned Media" : single blinded study - Wrinkle-improving effect of an all-in-one gel containing "Immortalized Human Tooth Pulp Stem Cell Conditioned Media" and "Human Cord Blood Stem Cell Conditioned Media"

Start Date04 Apr 2023

Sponsor / Collaborator-

CTR20211389

/ Active, not recruitingPhase 1

牙周基础治疗联合人牙髓间充质干细胞注射液治疗慢性牙周炎的随机、双盲、剂量递增、（空白）对照的安全性、耐受性临床试验

[Translation] A randomized, double-blind, dose-escalation, (blank)-controlled safety and tolerability clinical trial of periodontal basic therapy combined with human dental pulp mesenchymal stem cell injection in the treatment of chronic periodontitis

主要目的：探索人牙髓间充质干细胞治疗慢性牙周炎的安全性和耐受性。次要目的：剂量探索，为后续临床研究的给药方案提供设计依据；探索人牙髓间充质干细胞治疗慢性牙周炎的初步有效性。

[Translation]

Main purpose: To explore the safety and tolerability of human dental pulp mesenchymal stem cells in the treatment of chronic periodontitis. Secondary purpose: To explore the dose, to provide a design basis for the dosing regimen of subsequent clinical studies; to explore the preliminary effectiveness of human dental pulp mesenchymal stem cells in the treatment of chronic periodontitis.

Start Date31 Jul 2021

Sponsor / Collaborator

Capital University of Medical Sciences

[+1]

100 Clinical Results associated with Allogeneic dental pulp mesenchymal stem cell therapy (Beijing SH Bio-Tech Corporation/Utooth Biological Technology)

Login to view more data

100 Translational Medicine associated with Allogeneic dental pulp mesenchymal stem cell therapy (Beijing SH Bio-Tech Corporation/Utooth Biological Technology)

Login to view more data

100 Patents (Medical) associated with Allogeneic dental pulp mesenchymal stem cell therapy (Beijing SH Bio-Tech Corporation/Utooth Biological Technology)

Login to view more data

100 Deals associated with Allogeneic dental pulp mesenchymal stem cell therapy (Beijing SH Bio-Tech Corporation/Utooth Biological Technology)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Periodontitis	Phase 2	China	Capital University of Medical Sciences	13 Nov 2023
Chronic Periodontitis	Phase 2	China	Beijing Sanyouli Heze Biological Technology Co. Ltd.	13 Nov 2023
Post Acute COVID 19 Syndrome	Phase 2	China	Beijing Sanyouli Heze Biological Technology Co. Ltd.	06 May 2020
Post Acute COVID 19 Syndrome	Phase 2	China	Utooth Biological Technology Co., Ltd. Hubei (CN)	06 May 2020
Intrabony periodontal defect	Phase 1	China	Capital University of Medical Sciences	31 Jul 2021
Intrabony periodontal defect	Phase 1	China	Beijing Sanyouli Heze Biological Technology Co. Ltd.	31 Jul 2021
Psoriasis	IND Application	China	Beijing Sanyouli Heze Biological Technology Co. Ltd.	30 Jan 2022
Paraquat Lung	Preclinical	China	Beijing Sanyouli Heze Biological Technology Co. Ltd.	30 Jan 2022
Pulmonary Disease, Chronic Obstructive	Preclinical	China	Beijing Sanyouli Heze Biological Technology Co. Ltd.	30 Jan 2022
Pulmonary Fibrosis	Preclinical	China	Beijing Sanyouli Heze Biological Technology Co. Ltd.	30 Jan 2022